(Q38179453)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24437461%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

title

Clinical implications of irregular ADMET properties with levodopa and other antiparkinson's drugs (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24437461%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24437461%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

author name string

Livia Dézsi

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24437461%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

language of work or name

English

0 references

publication date

17 January 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24437461%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Drug Metabolism & Toxicology

5 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24437461%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

volume

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24437461%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24437461%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

page(s)

409-424

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24437461%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.878702

The hypothesis of the genesis of motor complications and continuous dopaminergic stimulation in the treatment of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.878702

Gastrointestinal dysfunction in Parkinson's disease: frequency and pathophysiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.878702

Gastric emptying in Parkinson's disease: patients with and without response fluctuations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.878702

Impact of gastric emptying on levodopa pharmacokinetics in Parkinson disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.878702

Helicobacter pylori infection and motor fluctuations in patients with Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.878702

Motor fluctuations and Helicobacter pylori in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.878702

Small intestinal bacterial overgrowth: diagnosis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.878702

Nicotine reduces L-DOPA-induced dyskinesias by acting at beta2* nicotinic receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.878702

Nicotinic receptor agonists reduce L-DOPA-induced dyskinesias in a monkey model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.878702

Chronic high dose transdermal nicotine in Parkinson's disease: an open trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.878702

Transdermal nicotine in PD: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.878702

Effect of nicotine on the pharmacokinetics of levodopa

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.878702

Levodopa in the early treatment of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.878702

The effect of carbidopa on the pharmacokinetics of intravenously administered levodopa: the mechanism of action in the treatment of parkinsonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.878702

Current pharmacotherapeutic treatment options in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.878702

Comparison of pharmacokinetic profile of levodopa throughout the day between levodopa/carbidopa/entacapone and levodopa/carbidopa when administered four or five times daily

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.878702

Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.878702

Toxicology and Safety of Comt Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.878702

COMT inhibition with tolcapone in the treatment algorithm of patients with Parkinson's disease (PD): relevance for motor and non-motor features

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.878702

Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.878702

Levodopa: is toxicity a myth?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.878702

Levodopa in the treatment of Parkinson's disease: current controversies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.878702

Levodopa and the progression of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.878702

Molecular and clinical pathways to neuroprotection of dopaminergic drugs in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.878702

Perspectives on recent advances in the understanding and treatment of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.878702

The impact of levodopa on quality of life in patients with Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.878702

Continuous drug delivery in early- and late-stage Parkinson's disease as a strategy for avoiding dyskinesia induction and expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.878702

Pathophysiology of motor fluctuations in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.878702

Levodopa delivery systems: advancements in delivery of the gold standard

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.878702

Pulsatile or continuous dopaminomimetic strategies in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.878702

Avoidance of dyskinesia: preclinical evidence for continuous dopaminergic stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.878702

Practice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.878702

Continuous dopaminergic stimulation reduces risk of motor complications in parkinsonian primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.878702

Continuous dopaminergic delivery to minimize motor complications in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.878702

Pharmacokinetics of levodopa, carbidopa, and 3-O-methyldopa following 16-hour jejunal infusion of levodopa-carbidopa intestinal gel in advanced Parkinson's disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.878702

Drug therapy in patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.878702

Apomorphine and levodopa infusion therapies for advanced Parkinson's disease: selection criteria and patient management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.878702

Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.878702

Peripheral neuropathy in Parkinson's disease: levodopa exposure and implications for duodenal delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.878702

Levodopa-carbidopa intestinal gel in advanced Parkinson's disease open-label study: interim results

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.878702

Optimizing levodopa therapy for Parkinson's disease with levodopa/carbidopa/entacapone: implications from a clinical and patient perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.878702

IPX066: a novel carbidopa-levodopa extended-release formulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.878702

Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.878702

Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.878702

Continuous dopaminergic stimulation: Is it the answer to the motor complications of Levodopa?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.878702

Novel (-)deprenyl-derived selective inhibitors of B-type monoamine oxidase. The relation of structure to their action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.878702

Pharmacological therapy in Parkinson's disease: focus on neuroprotection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.878702

Pharmacological aspects of (-)-deprenyl

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.878702

Clinical Pharmacokinetics and Pharmacodynamics of Selegiline

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.878702

The pharmacokinetic evaluation of selegiline ODT for the treatment of Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.878702

Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.878702

Rasagiline in Parkinson's disease: a review based on meta-analysis of clinical data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.878702

Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.878702

Clinical review and treatment of select adverse effects of dopamine receptor agonists in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.878702

Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.878702

Effects of a dopamine agonist on the pharmacodynamics of levodopa in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.878702

Once-daily pramipexole for the treatment of early and advanced idiopathic Parkinson's disease: implications for patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.878702

Apomorphine for the acute treatment of "off" episodes in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.878702

Current approaches to the treatment of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.878702

Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.878702

Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.878702

Absorption, disposition, metabolic fate, and elimination of the dopamine agonist rotigotine in man: administration by intravenous infusion or transdermal delivery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.878702

Determination of the dopamine D2 agonist N-0923 and its major metabolites in perfused rat livers by HPLC-UV-atmospheric pressure ionization mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.878702

Emerging therapies for Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.878702

Long-term efficacy and safety of safinamide as add-on therapy in early Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.878702

Novel therapy in Parkinson's disease: adenosine A(2A) receptor antagonists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.878702

Some molecular mechanisms of dopaminergic and glutamatergic dysfunctioning in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.878702

The role of kynurenines in disorders of the central nervous system: possibilities for neuroprotection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.878702

Kynurenines in chronic neurodegenerative disorders: future therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.878702

Kynurenines in the CNS: recent advances and new questions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.878702

Kynurenines in Parkinson's disease: therapeutic perspectives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.878702

Kynurenine metabolism in plasma and in red blood cells in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.878702

Altered tryptophan metabolism in Parkinson's disease: a possible novel therapeutic approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.878702

Prolonged kynurenine 3-hydroxylase inhibition reduces development of levodopa-induced dyskinesias in parkinsonian monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.878702

Decreased expression of kynurenine aminotransferase-I (KAT-I) in the substantia nigra of mice after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.878702

Prevalence of Small Intestinal Bacterial Overgrowth in Parkinson's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.878702

10.1517/17425255.2014.878702

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24437461%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

1 reference